Table 2 Use of study medication during follow-up
Follow-up time and study medication | HBPM group (n = 96) | Control group (n = 405) | P |
|---|---|---|---|
2 weeks, n (%) | |||
Discontinuation of treatment | 0 | 23 (5.7) | 0.03 |
Use of study medication | 96 | 382 (94.3) | |
4 weeks, n (%) | |||
Discontinuation of treatment | 0 | 12 (3.1) | 0.16 |
Use of study medication | 96 | 370 (96.9) | |
Irbesartan 150 mg/hydrochlorothiazide 12.5 mg | 87 (90.6) | 325 (87.8) | 0.45 |
Irbesartan 300 mg/hydrochlorothiazide 12.5–25 mg | 9 (9.4) | 45 (12.2) | |
8 weeks, n (%) | |||
Discontinuation of treatment | 0 | 5 (1.4) | 0.56 |
Use of study medication | 96 | 365 (90.1) | |
Irbesartan 150 mg/hydrochlorothiazide 12.5 mg | 70 (72.9) | 236 (64.7) | 0.13 |
Irbesartan 300 mg/hydrochlorothiazide 12.5–25 mg | 26 (27.1) | 129 (35.3) | |
12 weeks, n (%) | |||
Discontinuation of treatment | 1 (1.0) | 11 (3.0) | 0.09 |
Use of study medication | 95 | 354 (97.0) | |
Irbesartan 150 mg/hydrochlorothiazide 12.5 mg | 60 (63.2) | 210 (59.3) | 0.50 |
Irbesartan 300 mg/hydrochlorothiazide 12.5–25 mg | 35 (36.8) | 144 (40.7) |
